Funding and acquisition costs
Equity placements supported exploration; Weld Range added A$1.100m to the acquisition-cost asset, including non-cash consideration.
Mount Ridley’s financial record is not just a sequence of exploration losses. Ordinary exploration is expensed, acquisition costs sit separately on the balance sheet, and investments have supplied both gains and cash. In FY2025 the remaining exploration acquisition-cost asset was fully impaired, while selling listed investments helped fund continued operations without an in-year share raise.
Reading the figures: Units are stated above each table or beside the metric. Brackets denote negative amounts. Supported nil is shown as zero; unlike reporting bases remain separately labelled.
Before subsequent capital raising.
Already includes exploration cash payments.
Closing accounting asset is nil.
Cash receipt, not the realised gain.
The company reports mineral exploration, with Mount Ridley focused on rare earth elements and Weld Range West on iron and gold. Its accounting capitalises acquisition costs but expenses other exploration: the capitalised asset is not a running total of all drilling expenditure.
Equity receipts supported expansion through FY2023. The following two years had no comparable share-cash inflow, and cash declined even as exploration payments reduced. FY2025 securities sales partly offset that use of funds.
FY2025’s full exploration-asset impairment explains the apparent missing closing value. That is a recoverability decision under the accounting policy, not a finding that mineralisation or project rights ceased to exist.
Equity placements supported exploration; Weld Range added A$1.100m to the acquisition-cost asset, including non-cash consideration.
Exploration expense increased while financial investments produced a large fair-value loss, deepening the statutory result.
Exploration cash payments of A$3.894m were within operating cash flow; share receipts of A$5.783m helped lift closing cash.
REE beneficiation and drilling work continued. The A$0.999m refund received in this year related to FY2023 research activity.
The E&E asset was impaired to nil. Sale of listed shares brought cash while the company disclosed a continuing funding uncertainty.
Exploration expense was the largest recurring programme cost, but changes in the statutory loss also reflect R&D income and financial investments. The FY2024 share-based-payment reversal and FY2025 impairment should not be confused with cash paid to employees or drillers.
A$ million
AI-generated presentation · values from Five-year result: ordinary exploration is expensed; no missing values plotted as zero.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue from continuing operations (not mining sales) | 0.006 | 0.010 | 0.037 | 0.087 | 0.229 |
| Dividend income | 0.041 | 0.039 | 0.025 | 0.024 | 0.024 |
| Exploration expenditure expensed | (1.172) | (2.279) | (4.065) | (2.404) | (0.557) |
| Consulting expenses | (0.147) | (0.147) | (0.247) | (0.217) | (0.238) |
| Compliance and regulatory expenses | (0.116) | (0.142) | (0.187) | (0.077) | (0.141) |
| Directors fees | (0.141) | (0.156) | (0.144) | (0.156) | (0.175) |
| Administration expenses | (0.221) | (0.216) | (0.340) | (0.271) | (0.177) |
| Depreciation | (0.006) | (0.031) | (0.086) | (0.085) | (0.051) |
| Loss after tax | (0.944) | (4.312) | (4.647) | (1.985) | (2.644) |
Acquisition costs are capitalised in E&E; other exploration expenditure is expensed under the disclosed policy. Consequently ordinary exploration spending can be large while the capitalised asset changes little.
Selected recurring lines do not sum to total loss: R&D income, investment gains/losses, loan impairment and the FY2025 E&E impairment also matter. Revenue in FY2025 comprises interest, rent and other income, not mineral sales.
The FY2025 P&L extraction reports exploration expense of A$556,524; a detailed expense-note extraction records A$556,224. The A$300 conflict is retained, using the face-statement value here without inferring a source correction.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
A$ million
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| R&D income | 0.647 | 0.999 | 0.224 |
| Share-based payment expense / reversal | (0.147) | 0.147 | 0.000 |
| Loan impairment | (0.033) | (0.019) | (0.053) |
FY2024 share-based payments are a positive reversal, not an additional expense. FY2025 separately includes A$1.710m impairment of the E&E asset.
FY2021 recorded an A$0.815m financial-investment fair-value gain; FY2022 recorded an A$1.343m loss. Those movements, and the FY2025 realised gain, are not mineral operating margins.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
Subtracting exploration payments again from operating cash flow would double-count them. With that boundary respected, the cash-flow table shows equity inflows supporting earlier years and investment disposals cushioning FY2025. The listed-share sale is not a sale of mined product.
A$ million
AI-generated presentation · values from Cash flow by activity—including exploration inside operations; no missing values plotted as zero.
A$ million
AI-generated presentation · values from Cash flow by activity—including exploration inside operations; no missing values plotted as zero.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | (1.582) | (3.244) | (3.986) | (2.048) | (1.016) |
| Investing cash flow | (0.026) | 0.349 | (0.253) | 0.005 | 0.598 |
| Financing cash flow | 2.658 | 3.710 | 5.446 | (0.036) | (0.025) |
| Net cash movement | 1.049 | 0.814 | 1.207 | (2.079) | (0.442) |
| Closing cash | 1.449 | 2.264 | 3.470 | 1.392 | 0.950 |
Exploration payments are already part of operating cash flow. Do not add them again when comparing total cash use. Investing flows include securities transactions, dividends, acquisition payments and loans to third parties.
FY2024–FY2025 negative financing represents lease repayments. It does not mean share capital was redeemed. The positive FY2021 cash movement is confirmed by opening and closing balances; a later comparative has an inconsistent minus sign.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Payments to suppliers and employees | (0.418) | (0.773) | (0.780) | (0.574) | (0.635) |
| Exploration payments — included in operating cash flow | (1.165) | (2.477) | (3.894) | (2.550) | (0.640) |
| Dividends received — investing cash | 0.024 | 0.055 | 0.024 | 0.024 | 0.024 |
| Listed-share sale proceeds | 0.000 | 0.597 | 0.000 | 0.000 | 0.591 |
| Share-issue proceeds | 2.696 | 3.737 | 5.783 | 0.000 | 0.000 |
The share-issue row ends at FY2024; FY2025 financing consists solely of the A$24,751 lease repayment. No in-year placement is invented from the later capital-raising announcement.
FY2023/FY2024/FY2025 R&D cash receipts were A$0.647m/A$0.999m/A$0.224m, within operating cash. A refund relating to an earlier research year is dated to the financial period when received.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
The movement note starts FY2025 at A$1.710032m, records impairment of the same amount, and closes at a dash. The P&L and asset totals corroborate a nil balance. Showing this as unavailable would hide the main accounting event of the year.
The history before that impairment reflects acquisition costs and surrendered tenements. Under the policy, current exploration costs are generally expensed, so spending trends and carrying values should not be expected to move together.
A$ million
AI-generated presentation · values from Acquisition-cost asset: the nil FY2025 balance is explainable; no missing values plotted as zero.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Opening E&E carrying value | 0.783 | 1.883 | 1.949 | 1.949 | 1.710 |
| Closing E&E carrying value | 1.883 | 1.949 | 1.949 | 1.710 | 0.000 |
FY2021 added A$1.100m for Weld Range; FY2022 added A$70,915 of stamp duty and removed A$4,114 of surrendered tenements. FY2023 had no acquisition or surrender movement. FY2024 surrendered tenements reduced the asset by A$239,459.
FY2025 opening A$1.710032m was impaired in full. The dash in the closing balance therefore means nil here, corroborated by the P&L charge and balance sheet; it is not a value withheld as unavailable.
A zero accounting carrying value does not mean zero geological resources or that all project rights were relinquished. The disclosed indicators were market conditions and uncertainty over future exploration expenditure.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
A$ million
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Other current receivables | 0.147 | 0.186 | 0.145 | 0.145 | 0.054 |
| Other financial assets | 2.404 | 0.464 | 0.386 | 0.398 | 0.001 |
| Current assets | 4.000 | 2.913 | 4.001 | 1.935 | 1.004 |
| Current liabilities | 0.384 | 0.161 | 0.455 | 0.162 | 0.052 |
| Property, plant and equipment | 0.047 | 0.224 | 0.386 | 0.275 | 0.206 |
| Total assets | 5.930 | 5.167 | 6.413 | 3.964 | 1.210 |
| Total liabilities | 0.384 | 0.212 | 0.478 | 0.162 | 0.052 |
| Issued capital | 28.996 | 32.718 | 38.197 | 38.197 | 38.197 |
| Total equity | 5.546 | 4.956 | 5.935 | 3.802 | 1.158 |
The FY2025 investment balance is A$540, displayed as A$0.001m after rounding—not a missing value. Current assets are not all cash.
FY2025 current lease liability and right-of-use assets are explicitly nil following the lease repayments. The A$52,207 remaining liabilities are trade/other payables; they are not equated to bank borrowings.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
Selling the listed holding generated about A$0.591m of cash. The recognised gain was only A$0.193m after the opening carrying value. The small remaining financial asset was not that sold listed holding. Loans made to third parties are also investments/receivables, not borrowings by Mount Ridley.
The A$52,897 advanced for Weld Range due diligence had no fixed repayment terms and was impaired at year-end. Gross unsecured loans receivable totalled A$248,906, with a matching full impairment provision. These are asset-side credit exposures, not Group debt, and the loan impairment is separate from the much larger E&E impairment.
A$ million
| Metric | FY2025 |
|---|---|
| Opening listed holding | 0.397 |
| Sale movement in investment note | (0.591) |
| Realised gain | 0.193 |
| Closing listed holding | 0.000 |
The note shows A$590,641 sale proceeds versus A$590,642 in the cash statement—a retained A$1 difference. Realised gain is A$193,170; it is not the gross cash receipt. A separate A$540 unlisted holding remains in financial assets.
Source: Annual-report extractions; report editions are listed once in the consolidated source registry.
Both the FY2024 and FY2025 evidence identifies material going-concern uncertainty. Directors used the going-concern basis, citing spending flexibility and access to funding; the FY2025 auditor’s opinion was not modified in respect of the uncertainty.
The subsequent-events detail announced up to A$830,388 before costs on15August2025: a A$233,546 placement and rights issue up to about A$596,841. A separate going-concern summary calls A$830,388 raised. Because the saved records differ on completion status, this review does not claim the full maximum was received or add it to June cash.
A one-for-ten share consolidation completed in November2024. Per-share comparatives were restated, while issued-capital dollars remained unchanged. A smaller share count is not new funding or a tenfold change in the business’s assets.
Prepared solely from the existing year-by-year extraction datasets. No raw annual-report body, PDF, new database lookup or financial web research was used. Review is against those stored extractions, not a new independent original-document audit.
The source references in this report identify the public disclosures used and should be read with the associated section, table and reporting-period qualifications. This report paraphrases, organises and compares those disclosures for descriptive and educational purposes rather than reproducing source text.
Copyright and other rights in linked reports, company names, logos and third-party materials remain with their respective owners. MII Research does not claim affiliation with or endorsement by the company covered in this report, the ASX or cited organisations.
This report uses AI actively and extensively for evidence extraction, comparison, organisation, calculation checks, drafting, translation planning and presentation. Material claims received reasonable editorial review against cited public sources; this was not an audit, assurance engagement or independent verification. Limitations in public sources, AI systems and review may leave errors, omissions, inconsistencies or translation, classification and interpretation errors.
Any AI-generated visual accompanying this report must carry an adjacent, visible AI-generated label or caption. Such visuals are illustrative rather than source evidence and do not replace the cited annual-report text, table or section source.
This record is for general descriptive and educational information only. It is not financial-product, investment, legal, tax, technical or other professional advice; it is not a securities recommendation, valuation, target price, offer, solicitation or invitation to buy, sell or hold.
It does not consider any reader’s objectives, financial situation, needs, knowledge, experience or risk tolerance. Independently verify material information against the primary disclosures, obtain appropriate independent professional advice and do not use this record as the sole or primary basis for any decision.
Public sources are used in good faith, but no representation or warranty is made as to accuracy, completeness, reliability, currency or fitness for a particular purpose. To the maximum extent permitted by law, MII Research disclaims liability for direct, indirect, incidental, consequential, opportunity or investment loss arising from use of or reliance on this record; nothing excludes or limits liability that cannot lawfully be excluded or limited.
Report suspected errors to MII Research with the relevant report section and primary-source document and page reference so that the record can be reviewed and corrected where appropriate.